These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 10216137)

  • 1. A paucity of unusual trihydroxy bile acids in the urine of patients with severe liver diseases.
    Nakashima T; Sakamoto Y; Inaba K; Mitsuyoshi H; Ishikawa H; Nakajima Y; Sakai M; Shima T; Kashima K
    Hepatology; 1999 May; 29(5):1518-22. PubMed ID: 10216137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unusual trihydroxylated bile acids in urine of patients with liver cirrhosis.
    Amuro Y; Hayashi E; Endo T; Higashino K; Kishimoto S
    Clin Chim Acta; 1983 Jan; 127(1):61-7. PubMed ID: 6825311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual trihydroxy bile acids in the urine of patients treated with chenodeoxycholate, ursodeoxycholate or rifampicin and those with cirrhosis.
    Nakashima T; Sano A; Seto Y; Nakajima T; Shima T; Sakamoto Y; Okuno T; Kashima K; Hasegawa T
    Hepatology; 1990 Feb; 11(2):255-60. PubMed ID: 2307404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unusual trihydroxy bile acids in the urine of healthy humans.
    Nakashima T; Sano A; Seto Y; Nakajima T; Nakagawa Y; Okuno T; Takino T; Hasegawa T
    Clin Chim Acta; 1986 Oct; 160(1):47-53. PubMed ID: 3769218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy.
    Nakamura K; Yoneda M; Kimura A; Tamori K; Yokohama S; Sato Y; Kato T; Hasegawa T; Saito H; Aoshima M; Fujita M; Makino I
    J Gastroenterol Hepatol; 1996 Apr; 11(4):385-90. PubMed ID: 8713707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursocholic acid, a hydrophilic bile acid, fails to improve liver function parameters in primary biliary cirrhosis: comparison with ursodeoxycholic acid.
    Batta AK; Salen G; Abroon J
    Am J Gastroenterol; 1997 Jun; 92(6):1035-7. PubMed ID: 9177526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfated and nonsulfated bile acids in urine, serum, and bile of patients with hepatobiliary diseases.
    Makino I; Hashimoto H; Shinozaki K; Yoshino K; Nakagawa S
    Gastroenterology; 1975 Mar; 68(3):545-53. PubMed ID: 1112456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered bile acid metabolism in liver disease: concurrent occurrence of C-1 and C-6 hydroxylated bile acid metabolites and their preferential excretion into urine.
    Shoda J; Tanaka N; Osuga T; Matsuura K; Miyazaki H
    J Lipid Res; 1990 Feb; 31(2):249-59. PubMed ID: 2324645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
    Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
    Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent occurrence of 3 beta,12 alpha-dihydroxy-5-cholenoic acid associated with 3 beta-hydroxy-5-cholenoic acid and their preferential urinary excretion in liver diseases.
    Shoda J; Osuga T; Matsuura K; Mahara R; Tohma M; Tanaka N; Matsuzaki Y; Miyazaki H
    J Lipid Res; 1989 Aug; 30(8):1233-42. PubMed ID: 2769075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different bile acid-phospholipid conjugates in acute hepatitis.
    Pathil A; Warth A; Chamulitrat W; Stremmel W
    Eur J Clin Invest; 2012 Feb; 42(2):130-8. PubMed ID: 21707612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.
    Combes B; Carithers RL; Maddrey WC; Munoz S; Garcia-Tsao G; Bonner GF; Boyer JL; Luketic VA; Shiffman ML; Peters MG; White H; Zetterman RK; Risser R; Rossi SS; Hofmann AF
    Hepatology; 1999 Jun; 29(6):1649-54. PubMed ID: 10347103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ursodeoxycholic acid on synthesis of cholesterol and bile acids in healthy subjects.
    Sauter GH; Thiessen K; Parhofer KG; Jüngst C; Fischer S; Jüngst D
    Digestion; 2004; 70(2):79-83. PubMed ID: 15375335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps.
    Batta AK; Salen G; Holubec H; Brasitus TA; Alberts D; Earnest DL
    Cancer Res; 1998 Apr; 58(8):1684-7. PubMed ID: 9563483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aspects of bile acid metabolism in liver diseases(author's transl)].
    Horak W
    Acta Med Austriaca Suppl; 1975; 4():1-38. PubMed ID: 1064281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids.
    Clayton PT; Leonard JV; Lawson AM; Setchell KD; Andersson S; Egestad B; Sjövall J
    J Clin Invest; 1987 Apr; 79(4):1031-8. PubMed ID: 3470305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
    Marschall HU; Wagner M; Zollner G; Fickert P; Diczfalusy U; Gumhold J; Silbert D; Fuchsbichler A; Benthin L; Grundström R; Gustafsson U; Sahlin S; Einarsson C; Trauner M
    Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.